伴有t（8;21）染色体异常急性髓系白血病的免疫表型特征

本研究主要探讨具有t（8;21）（q22;q22）染色体改变的急性髓系白血病（acute myeloid leukemia,AML）患者的免疫表型及伴随的染色体异常。利用多参数流式细胞仪（multiparameter flow cytometry,MPFC）检测和分析47例具有t（8;21）的AML患者白血病细胞免疫表型。结果表明：47例t（8;21）-AML中21例（44.68%）伴有其他染色体异常,26例（55.32%）为单纯t（8;21）染色体改变。多参数流式检测结果提示：t（8;21）-AML患者干/祖细胞标记CD34、CD117和HLA-DR阳性率分别为87.2%、97.9%和95.7%,髓系标记CD13和CD33阳性率分别为93.6%和87.2%,T淋巴系标记CD2、CD3、CD5和CD7未见表达,B淋巴系标记CD19阳性率为66.0%,显著高于其他B淋巴系标记CD20和CD22,同时NK细胞标记CD56阳性率亦高达66.7%。结论：利用多参数流式细胞术检测t（8;21）-AML发现该亚型AML具有较为特异性的免疫表型特征：干祖细胞标志（CD34、CD117和HLA-DR）表达较高,并且B淋系标志CD19和NK细胞标志CD56表达明显较高,提示联合CD34/CD19/CD56检测可以成为预测AML可能具有t（8;21）（q22;q22）的染色体改变准确而快速的临床指标。

Immunophenotypic Analysis of Acute Myeloid Leukemia with t(8;21)

This study was aimed to investigate laboratorial characteristics of immunophenotyping and concurrent karyotypic aberrations in acute myeloid leukemia with t（8;21）（q22;q22）. A total number of 47 AML patients with t（8;21） were enrolled in this study and immunophenotypic antigens were detected by multiparameter flow cytometry. The results indicated that the additional karyotypic aberrations were found in 21 out of 47 AML patients with t（8;21）（q22;q22（44.68%）, single karyotypic aberration was observed in 26 out of 47 AML patients with t（8;21）（q22;q22）（55.32%）. The positive rate of stem/progenitor cell markers of CD34, CD117 and HLA-DR were 87.2%, 97.9% and 95.7% respectively. Myeloid markers of CD13 and CD33 were 93.6% and 87.2%, and there were nearly no expre-ssion of T lineage antigens（CD2, CD3, CD5 and CD7） detected in t（8;21）-AML. CD19, one of a pan-B markers was found in 66.0% of all 47 t（8;21）-AML patients as well as CD56（66.7%）, which was significant higher than other B lineage antigens（CD20 and CD22）. It is concluded that AML with t（8;21） displays an exclusive immunophenotyping with significantly high expression of CD19 and CD56 as well as precursor cell markers（CD34, CD117 and HLA-DR） and combination detection of CD34/CD19/CD56 may become a predictive indicator of t（8;21）（q22;q22） cytogenetic abnormality.